May 20 (Reuters) - Neuphoria Therapeutics Inc NEUP.O:
NEUPHORIA THERAPEUTICS INC - CASH RUNWAY EXTENDS INTO Q3 2026 - SEC FILING
NEUPHORIA THERAPEUTICS INC - AFFIRM-1 PHASE 3 TRIAL OF BNC-210 TOPLINE READOUT EXPECTED Q3 2025 - SEC FILING
Source text: [ID:n0001213900-25-045970]
Further company coverage: NEUP.O
((Reuters.Brief@thomsonreuters.com;))